AU2021300363A1 - Pyridine-1,5-diones exhibiting MNK inhibition and their method of use - Google Patents
Pyridine-1,5-diones exhibiting MNK inhibition and their method of use Download PDFInfo
- Publication number
- AU2021300363A1 AU2021300363A1 AU2021300363A AU2021300363A AU2021300363A1 AU 2021300363 A1 AU2021300363 A1 AU 2021300363A1 AU 2021300363 A AU2021300363 A AU 2021300363A AU 2021300363 A AU2021300363 A AU 2021300363A AU 2021300363 A1 AU2021300363 A1 AU 2021300363A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046325P | 2020-06-30 | 2020-06-30 | |
| US63/046,325 | 2020-06-30 | ||
| PCT/US2021/039982 WO2022006331A2 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibitng mnk inhibition and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021300363A1 true AU2021300363A1 (en) | 2023-02-09 |
Family
ID=79315594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021300363A Pending AU2021300363A1 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibiting MNK inhibition and their method of use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230286983A1 (https=) |
| EP (1) | EP4171565A4 (https=) |
| JP (1) | JP2023533616A (https=) |
| KR (1) | KR20230041715A (https=) |
| CN (1) | CN116194112A (https=) |
| AU (1) | AU2021300363A1 (https=) |
| BR (1) | BR112022026275A2 (https=) |
| CA (1) | CA3183551A1 (https=) |
| IL (1) | IL299512A (https=) |
| MX (1) | MX2022016516A (https=) |
| WO (1) | WO2022006331A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225747A1 (en) * | 2021-06-30 | 2023-01-05 | 4E Therapeutics, Inc. | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| CN103874496A (zh) * | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017068064A1 (en) * | 2015-10-22 | 2017-04-27 | Selvita S.A. | Pyridone derivatives and their use as kinase inhibitors |
| BR112018008711A2 (pt) * | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2 |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017165908A1 (en) * | 2016-03-31 | 2017-10-05 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| CN113286592A (zh) * | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110256432A (zh) * | 2019-06-27 | 2019-09-20 | 诺沃斯达药业有限公司 | 抑制mnk1和mnk2的多环化合物 |
-
2021
- 2021-06-30 JP JP2023524490A patent/JP2023533616A/ja active Pending
- 2021-06-30 WO PCT/US2021/039982 patent/WO2022006331A2/en not_active Ceased
- 2021-06-30 BR BR112022026275A patent/BR112022026275A2/pt unknown
- 2021-06-30 MX MX2022016516A patent/MX2022016516A/es unknown
- 2021-06-30 CA CA3183551A patent/CA3183551A1/en active Pending
- 2021-06-30 IL IL299512A patent/IL299512A/en unknown
- 2021-06-30 US US18/003,829 patent/US20230286983A1/en active Pending
- 2021-06-30 CN CN202180056845.0A patent/CN116194112A/zh active Pending
- 2021-06-30 KR KR1020237003174A patent/KR20230041715A/ko active Pending
- 2021-06-30 AU AU2021300363A patent/AU2021300363A1/en active Pending
- 2021-06-30 EP EP21831750.1A patent/EP4171565A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183551A1 (en) | 2022-01-06 |
| WO2022006331A3 (en) | 2022-02-10 |
| EP4171565A2 (en) | 2023-05-03 |
| EP4171565A4 (en) | 2024-11-27 |
| CN116194112A (zh) | 2023-05-30 |
| US20230286983A1 (en) | 2023-09-14 |
| MX2022016516A (es) | 2023-03-28 |
| KR20230041715A (ko) | 2023-03-24 |
| WO2022006331A9 (en) | 2022-03-03 |
| JP2023533616A (ja) | 2023-08-03 |
| WO2022006331A8 (en) | 2023-03-16 |
| WO2022006331A2 (en) | 2022-01-06 |
| IL299512A (en) | 2023-02-01 |
| BR112022026275A2 (pt) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| AU2014298051B2 (en) | Novel quinazolinones as bromodomain inhibitors | |
| US12030892B2 (en) | CRBN modulators | |
| US9314468B2 (en) | Chemokine receptor modulators | |
| US11766435B2 (en) | N3-substituted iminopyrimidinones as antimalarial agents | |
| US10968210B2 (en) | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| US20230158157A1 (en) | Potent and selective degraders of alk | |
| US12018001B2 (en) | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | |
| US20250205244A1 (en) | Methods of treating migraine with mnk inhibitors | |
| US20250186436A1 (en) | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use | |
| US20230286983A1 (en) | Pyridine-1,5-diones exhibiting mnk inhibition and their method of use | |
| KR20230069984A (ko) | Tyk2 억제제 및 그의 용도 | |
| US20240277852A1 (en) | Inhibitors and degraders of pip4k protein | |
| US20240400551A1 (en) | Nek7 inhibitors | |
| CA3214360A1 (en) | Pyrimidine derivatives useful as lrrk2 kinase inhibitors | |
| US20250177382A1 (en) | Nek7 inhibitors | |
| TW202523670A (zh) | Ｐｄｅ ７調節劑化合物 | |
| HK40034453B (zh) | 嘧啶环己烯基糖皮质激素受体调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE |